Latest Mergers And Acquisitions News

Clean Seas Seafood Limited shares have been suspended from the ASX following Federal Court approval of its acquisition by Yumbah Aquaculture Ltd, marking a significant consolidation in Australia’s seafood sector.

betr Entertainment has unveiled an all-scrip takeover bid for PointsBet, offering shareholders 3.81 betr shares per PointsBet share, valuing the offer above a competing cash bid and promising significant cost synergies.

betr Entertainment Limited has launched an all-scrip takeover bid for PointsBet Holdings Limited, offering 3.81 betr shares for every PointsBet share, valuing PointsBet at $1.22 per share and promising significant cost synergies.

Platinum Capital Limited has released detailed worked examples for its proposed scheme of arrangement, outlining a special dividend payout and the exchange ratio for shares into ETF units. The final dividend value and unit allocation will be confirmed closer to the scheme implementation date.

Platinum Asia Investments has released illustrative calculations for its Special Dividend and Scheme consideration tied to a proposed restructure, offering shareholders clarity ahead of a pivotal vote.

NSX Limited has updated its Scheme Implementation Deed with CNSX Markets Inc., extending the shareholder approval deadline and allowing greater flexibility in acquisition structuring.

Clean Seas Seafood’s takeover by Yumbah Aquaculture has been formally approved and registered, marking a key milestone in the seafood sector consolidation. Share trading is suspended as shareholders prepare for compensation.

United Overseas Australia Ltd has signed a binding agreement to acquire a strategic land parcel in Ho Chi Minh City, aiming to develop a substantial commercial office building. The AU$104.7 million deal marks a significant expansion into Vietnam’s growing property market.

Imugene Limited has launched a $37.5 million equity raising through a Placement and Share Purchase Plan, offering new shares and options to fund its pivotal azer-cel clinical program. The raise includes attaching and piggyback options, subject to shareholder approval, aiming to bolster the company’s immuno-oncology pipeline.

Kinterra Capital has lodged a formal review application against the Takeovers Panel’s earlier ruling involving New World Resources, signaling potential shifts in the ongoing corporate governance saga.

Imugene Limited has launched a A$37.5 million capital raising to advance its promising off-the-shelf CAR T therapy, azer-cel, following encouraging Phase 1b data showing a 75% overall response rate in lymphoma patients.

Imugene Limited has completed a $22.5 million institutional placement and launched a $15 million Share Purchase Plan, both featuring attaching options, to fund its azer-cel clinical program through a pivotal trial in 2026.